{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:08:21Z","timestamp":1778476101852,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Medical Association"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jnma.2025.06.007","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:41:03Z","timestamp":1752572463000},"page":"285-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enrollment of race\/ethnicity in ophthalmic clinical trials before and after the Final Rule"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7176-0694","authenticated-orcid":false,"given":"Deniz","family":"Goodman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0596-1903","authenticated-orcid":false,"given":"Minali","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-7387","authenticated-orcid":false,"given":"Nayan","family":"Sanjiv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara C.","family":"LaMattina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Ness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0061-098X","authenticated-orcid":false,"given":"Manju L.","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jnma.2025.06.007_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jnma.2025.06.007_bib0002","article-title":"Race\/ethnicity reporting and representation in US clinical trials: a cohort study","volume":"11","author":"Turner","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"12","key":"10.1016\/j.jnma.2025.06.007_bib0003","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2105\/AJPH.2011.300279","article-title":"Challenging assumptions about minority participation in US clinical research","volume":"101","author":"Fisher","year":"2011","journal-title":"Am J Public Health"},{"issue":"11","key":"10.1016\/j.jnma.2025.06.007_bib0004","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1001\/jamainternmed.2014.4758","article-title":"Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines","volume":"174","author":"Sardar","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"22","key":"10.1016\/j.jnma.2025.06.007_bib0005","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jnma.2025.06.007_bib0006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jamaophthalmol.2021.0857","article-title":"Racial\/ethnic disparities in ophthalmology clinical trials resulting in US Food and Drug Administration Drug approvals from 2000 to 2020","volume":"139","author":"Berkowitz","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.jnma.2025.06.007_bib0007","first-page":"123","article-title":"Race and ethnic representation among clinical trials for diabetic retinopathy and diabetic macular edema within the United States: a review","volume":"114","author":"Sanjiv","year":"2022","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.jnma.2025.06.007_bib0008","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ajo.2020.09.042","article-title":"The impact of race on short-term treatment response to bevacizumab in diabetic macular edema","volume":"222","author":"Osathanugrah","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jnma.2025.06.007_bib0009","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3928\/23258160-20210330-05","article-title":"Racial differences in anti-VEGF intravitreal injections among commercially insured beneficiaries","volume":"52","author":"Al-Moujahed","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"6","key":"10.1016\/j.jnma.2025.06.007_bib0010","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ophtha.2010.10.024","article-title":"Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups","volume":"118","author":"Stein","year":"2011","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.jnma.2025.06.007_bib0011","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2337\/diacare.28.8.1954","article-title":"Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial","volume":"28","author":"Emanuele","year":"2005","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jnma.2025.06.007_bib0012","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0039-6257(03)00028-6","article-title":"Primary open-angle glaucoma in blacks: a review","volume":"48","author":"Racette","year":"2003","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jnma.2025.06.007_bib0013","unstructured":"Dastmalchi L, Gulati M. Increasing the number of women and underrepresented groups in clinical trials. https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2022\/12\/09\/13\/06\/Increasing-the-Number-of-Women-and-Underrepresented-Groups-in-Clinical-Trials#:\u223c:text=Efforts%20have%20been%20made%20at,by%20the%20Food%20and%20Drug"},{"key":"10.1016\/j.jnma.2025.06.007_bib0014","unstructured":"FDAAA 801 and the final rule - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/manage-recs\/fdaaa"},{"issue":"20","key":"10.1016\/j.jnma.2025.06.007_bib0017","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMsr1611785","article-title":"Trial reporting in ClinicalTrials.gov \u2014 the final rule","volume":"375","author":"Zarin","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jnma.2025.06.007_bib0018","unstructured":"NIH Policy and guidelines on the inclusion of women and minorities as subjects in clinical research | grants.nih.gov."},{"key":"10.1016\/j.jnma.2025.06.007_bib0019","unstructured":"Commissioner O of the. Step 3: clinical research. . FDA. https:\/\/www.fda.gov\/patients\/drug-development-process\/step-3-clinical-research"},{"key":"10.1016\/j.jnma.2025.06.007_bib0020","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jnma.2025.06.007_bib0021","unstructured":"Office of Management and Budget (OMB) standards | Office of Research on Women\u2019s Health. . https:\/\/orwh.od.nih.gov\/toolkit\/other-relevant-federal-policies\/OMB-standards"},{"key":"10.1016\/j.jnma.2025.06.007_bib0022","unstructured":"Bias-free language. APA. https:\/\/apastyle-apa-org.ezproxy.bu.edu\/style-grammar-guidelines\/bias-free-language"},{"key":"10.1016\/j.jnma.2025.06.007_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106237","article-title":"Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications","volume":"101","author":"Fain","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"9","key":"10.1016\/j.jnma.2025.06.007_sbref0024","article-title":"Reporting and enrollment of women and racial minorities in ophthalmic clinical trials","volume":"60","author":"Hamid","year":"2019","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.jnma.2025.06.007_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100402","article-title":"Racial, ethnic, and gender diversity in United States Ophthalmology Clinical Trials","volume":"4","author":"Montazeri","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.jnma.2025.06.007_bib0026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/EDBK_100021","article-title":"Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy","volume":"39","author":"Nazha","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"10.1016\/j.jnma.2025.06.007_bib0027","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/cpt.2707","article-title":"The importance of diversity in clinical trials","volume":"113","author":"Johnson-Williams","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jnma.2025.06.007_bib0028","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamaophthalmol.2023.2289","article-title":"Prevalence of diabetic retinopathy in the US in 2021","volume":"141","author":"Lundeen","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jnma.2025.06.007_bib0029","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000455277","article-title":"Diabetic macular edema","volume":"58","author":"Bandello","year":"2017","journal-title":"Dev Ophthalmol"},{"issue":"2-3","key":"10.1016\/j.jnma.2025.06.007_sbref0030","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1017\/S0098858800002823","article-title":"The participation of underrepresented minorities in clinical research","volume":"29","author":"Noah","year":"2003","journal-title":"Am J Law Med"},{"issue":"4","key":"10.1016\/j.jnma.2025.06.007_bib0031","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.parkreldis.2008.06.005","article-title":"Minority enrollment in Parkinson's disease clinical trials","volume":"15","author":"Schneider","year":"2009","journal-title":"Park Relat Disord"},{"issue":"5","key":"10.1016\/j.jnma.2025.06.007_bib0032","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00000441-200111000-00002","article-title":"History of medical ethics and perspectives on disparities in minority recruitment and involvement in health research","volume":"322","author":"Seto","year":"2001","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.jnma.2025.06.007_bib0033","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0277-9536(00)00178-7","article-title":"African Americans' views on research and the Tuskegee Syphilis Study","volume":"52","author":"Freimuth","year":"2001","journal-title":"Soc Sci Med"},{"issue":"11","key":"10.1016\/j.jnma.2025.06.007_bib0034","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1001\/jamaophthalmol.2023.4638","article-title":"Diverse research teams and underrepresented groups in clinical studies","volume":"141","author":"Bains","year":"2023","journal-title":"JAMA Ophthalmol"}],"container-title":["Journal of the National Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968425000768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0027968425000768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:21:51Z","timestamp":1778473311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0027968425000768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0027968425000768"],"URL":"https:\/\/doi.org\/10.1016\/j.jnma.2025.06.007","relation":{},"ISSN":["0027-9684"],"issn-type":[{"value":"0027-9684","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enrollment of race\/ethnicity in ophthalmic clinical trials before and after the Final Rule","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnma.2025.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 National Medical Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}